Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Carboplatin in Metastatic Melanoma
NCT02223884Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Jul 2011
- Primary completion
- Aug 2014
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and carboplatin in Malignant Melanoma (MM), sponsored by Yonsei University. Primary endpoint: Overall Response Rate up to 4 years. Started Jul 2011; status: completed.
02
Drugs
docetaxelcarboplatin
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT02223884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223884.